Vitiligo

Currently Enrolling Vitiligo Studies

A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Topical Cream in Pediatric Participants With Nonsegmental Vitiligo

• Population: Patients 2 years of age and ≤ 11
• Study Condition: Nonsegmental Vitiligo
• Study Design: This study is a randomized, double-blind, vehicle-controlled phase 3 study with an open label, treatment-extension period to evaluate the safety and efficacy of an investigational topical cream in pediatric patients with nonsegmental vitiligo. Approximately 180 participants will be enrolled and randomized across study sites. There will be a 30-day screening period, a Double-Blind period for 24 weeks in which subjects will have been randomized to either the study cream BID or vehicle cream BID, followed by a 28 week open-label treatment extension period, and a safety follow-up period for 30 days.
• Duration: Approximately 14 months
• Compensation may be provided for participation.

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo

• Population: Participants must be between 18 and 75 years old at the time of signing informed consent.
• Study Condition: Participants must have a clinical diagnosis of nonsegmental vitiligo
• Study Design: This is a phase 2, multicenter, randomized, placebo-controlled double-blind, trial to evaluate the efficacy and safety of zasocitinib in participants with nonsegmental vitiligo.
• Duration: The maximum trial duration for an individual participant is approximately 61 weeks (427 days) including screening period of up to 35 days, a study treatment period of up to 52 weeks, and a 4-week safety follow-up period.
• Compensation is provided for participation